Psyence Biomedical LTD Schedule 13D activist filings

Psyence Labs Ltd. has filed a Schedule 13D, revealing beneficial ownership of 1,146,159 common shares, representing 30.05% of Psyence Biomedical Ltd., acquired through a share-for-share exchange.

KAOS Capital Ltd. and Adam Arviv have reduced their beneficial ownership in Psyence Biomedical Ltd. to 4.91% due to an increase in outstanding shares, while expressing significant concerns about current management.

KAOS Capital Ltd. and its CEO Adam Arviv have disclosed a 16.77% beneficial ownership stake in Psyence Biomedical Ltd., citing the company's securities as undervalued.

Psyence Group Inc. has sold all of its common shares in Psyence Biomedical Ltd. between May 2, 2025, and May 9, 2025, and is no longer a beneficial owner of more than 5% of the Issuer's common shares.

Psyence Group Inc. has filed an amended Schedule 13D, revealing a 14.99% beneficial ownership stake in Psyence Biomedical Ltd., primarily through a business combination and the acquisition of Psyence Labs Ltd.